| 551.21 -24.77 (-4.3%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 684.44  |
1-year : | 799.43 |
| Resists | First : | 586 |
Second : | 684.44 |
| Pivot price | 553.11 |
|||
| Supports | First : | 533.57 |
Second : | 501.17 |
| MAs | MA(5) : | 564.31 |
MA(20) : | 543.84 |
| MA(100) : | 547.13 |
MA(250) : | 599.59 |
|
| MACD | MACD : | 10.1 |
Signal : | 8.4 |
| %K %D | K(14,3) : | 79.1 |
D(3) : | 86.5 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 769.97 | Low : | 500.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IDXX ] has closed above bottom band by 47.0%. Bollinger Bands are 28.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 586.69 - 589.78 | 589.78 - 592.4 |
| Low: | 533.69 - 537 | 537 - 539.82 |
| Close: | 545.71 - 551.39 | 551.39 - 556.23 |
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Sat, 31 Oct 2026
IDEXX Laboratories (IDXX) Stock Looks Fairly Valued Despite Its 28% Run - Yahoo Finance
Fri, 30 Oct 2026
Is IDEXX Laboratories Inc (IDXX) a Bargain After 4.3% Drop? GF V - GuruFocus
Fri, 30 Oct 2026
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors - MarketWatch
Thu, 29 Oct 2026
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Thu, 29 Oct 2026
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
Wed, 28 Oct 2026
IDEXX Labs Price Target Cut to $627.00/Share From $670.00 by UBS - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 79 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 96.5 (%) |
| Shares Short | 1,940 (K) |
| Shares Short P.Month | 2,090 (K) |
| EPS | 14.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.44 |
| Profit Margin | 25 % |
| Operating Margin | 34.9 % |
| Return on Assets (ttm) | 27 % |
| Return on Equity (ttm) | 74.2 % |
| Qtrly Rev. Growth | 9.6 % |
| Gross Profit (p.s.) | 36.04 |
| Sales Per Share | 57.75 |
| EBITDA (p.s.) | 20.56 |
| Qtrly Earnings Growth | 17.6 % |
| Operating Cash Flow | 1,370 (M) |
| Levered Free Cash Flow | 909 (M) |
| PE Ratio | 38.73 |
| PEG Ratio | 3 |
| Price to Book value | 26.96 |
| Price to Sales | 9.54 |
| Price to Cash Flow | 31.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|